This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
Senanarong, Vorapun,
Poungvarin, Niphon,
Phanthumchinda, Kammant,
Thavichachart, Nuntika,
Chankrachang, Siwaporn,
Praditsuwan, Rungnirund,
Nidhinandana, Samart
The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]
Postmenopausal hormone therapy and subclinical cerebrovascular disease: the WHIMS-MRI Study
Coker, L. H.,
Hogan, P. E.,
Bryan, N. R.,
Kuller, L. H.,
Margolis, K. L.,
Bettermann, K.,
Wallace, R. B.,
Lao, Z.,
Freeman, R.,
Stefanick, M. L.,
Shumaker, S. A.
Objective: The Women’s Health Initiative Memory Study (WHIMS) hormone therapy (HT) trials reported that conjugated equine estrogen (CEE) with or without medroxyprogesterone acetate (MPA) increases risk for all-cause dementia and global cognitive decline. WHIMS MRI measured subclinical cerebrovascular disease as a possible mechanism to explain cognitive decline reported in WHIMS.; Methods: We contacted 2,345 women […]
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition
Espeland, Mark A.,
Shumaker, Sally A.,
Limacher, Marian,
Rapp, Stephen R.,
Bevers, Therese B.,
Barad, David H.,
Coker, Laura H.,
Gaussoin, Sarah A.,
Stefanick, Marcia L.,
Lane, Dorothy S.,
Maki, Pauline M.,
Resnick, Susan M.
Objective: To compare the relative effects of conjugated equine estrogens (CEE), raloxifene, and tamoxifen therapies on cognition among women aged > or =65 years.; Methods: Annual Modified Mini-Mental State (3MS) examinations were used to assess global cognitive function in the two randomized placebo-controlled clinical trials of CEE therapies of the Women’s Health Initiative Memory Study […]
Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment
Liu-Ambrose, Teresa,
Eng, Janice J.,
Boyd, Lara A.,
Jacova, Claudia,
Davis, Jennifer C.,
Bryan, Stirling,
Lee, Philip,
Brasher, Penny,
Hsiung, Ging-Yuek R.
Background: Sub-cortical vascular ischaemia is the second most common etiology contributing to cognitive impairment in older adults, and is frequently under-diagnosed and under-treated. Although evidence is mounting that exercise has benefits for cognitive function among seniors, very few randomized controlled trials of exercise have been conducted in populations at high-risk for progression to dementia. Aerobic-based […]
Alzheimer’s Disease Anti-inflammatory Prevention Trial: design, methods, and baseline results
Background: The Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT) was designed to address whether non-steroidal anti-inflammatory drugs (NSAIDs) can prevent or delay the onset of Alzheimer’s disease (AD).; Methods: ADAPT was a randomized, double-placebo-controlled, multicenter chemoprevention trial conducted at six U.S. dementia research clinics. At entry, participants were required to test “normal” on a battery of […]
Akatinol memantine in patients with vascular cognitive disorders
Treatment of cognitive disorders developed in cerebrovascular pathology is an actual medical problem. Of great importance is the timed diagnosis of these changes in the earlier phases of the development of cognitive deficit as well as adequate therapy that can delay and prevent the development of such complication as dementia. Pathogenetic mechanisms of cognitive disorders […]
Continuous dopaminergic stimulation by Duodopa in advanced Parkinson’s disease: Efficacy and safety
Annic, A.,
Devos, D.,
Seguy, D.,
Dujardin, K.,
Destée, A.,
Defebvre, L.
Introduction: When advanced Parkinson’s disease (PD) patients experience motor complications (fluctuations and dyskinesias) despite standard oral treatment, two treatment options are available: deep brain stimulation and subcutaneous apomorphine infusion with respects of indications for each strategy. Continuous intraduodenal infusion of levodopa (Duodopa) via a gastrojejunal tube may be proposed at this stage of the disease […]
Levetiracetam: a practical option for seizure management in elderly patients with cognitive impairment
Lippa, Carol F.,
Rosso, Andrea,
Hepler, Marjorie,
Jenssen, Sigmund,
Pillai, Jyoti,
Irwin, David
Cognitive impairment and seizures are common in our aging population. Anticonvulsant treatment is problematic due to sedation, cognitive slowing, and behavioral changes. Levetiracetam has favorable pharmacokinetics, good efficacy in elderly individuals, a favorable side effect profile, and lacks major drug interactions. We conducted a prospective, uncontrolled, phase 4, open label, 12-week study of levetiracetam to […]